Literature DB >> 18377935

Functional impairment in body dysmorphic disorder: a prospective, follow-up study.

Katharine A Phillips1, Gene Quinn, Robert L Stout.   

Abstract

Cross-sectional/retrospective studies indicate that individuals with body dysmorphic disorder (BDD) have markedly impaired psychosocial functioning. However, no study has prospectively examined functioning in BDD. In this study, which is to our knowledge the first prospective study of the course of BDD, psychosocial functioning was assessed at baseline and over 1-3 years (mean=2.7+/-0.9 years) of follow-up with the Global Assessment of Functioning scale (GAF), Social and Occupational Functioning Scale (SOFAS), and LIFE-RIFT (Range of Impaired Functioning Tool). Psychosocial functioning was poor during the follow-up period. Functioning remained stably poor over time on the SOFAS and LIFE-RIFT, although there was a trend for a gradual and slight improvement on the GAF over time. The cumulative probability of attaining functional remission on the GAF (score>70 for at least 2 consecutive months) during the follow-up period was only 5.7%. On the SOFAS, the cumulative probability of attaining functional remission (score>70 for at least 2 consecutive months) was 10.6%. BDD severity significantly predicted functioning on the GAF (p=0.0012), SOFAS (p=0.0017), and LIFE-RIFT (p=0.0015). A trend for a time-by-BDD severity interaction was found on the GAF (p=0.033) but not the SOFAS or LIFE-RIFT. More delusional BDD symptoms also predicted poorer functioning on all measures, although this finding was no longer significant when controlling for BDD severity. Functioning was not predicted, however, by age, gender, BDD duration, or a personality disorder. In conclusion, psychosocial functioning was poor over time, and few subjects attained functional remission. Greater BDD severity predicted poorer functioning.

Entities:  

Mesh:

Year:  2008        PMID: 18377935      PMCID: PMC2963020          DOI: 10.1016/j.jpsychires.2007.07.010

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  33 in total

Review 1.  Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients.

Authors:  D O'Leary; F Costello; N Gormley; M Webb
Journal:  J Affect Disord       Date:  2000 Jan-Mar       Impact factor: 4.839

Review 2.  Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

Authors:  A F Schatzberg; A J Rothschild
Journal:  Am J Psychiatry       Date:  1992-06       Impact factor: 18.112

3.  Quality of life for patients with body dysmorphic disorder.

Authors:  K A Phillips
Journal:  J Nerv Ment Dis       Date:  2000-03       Impact factor: 2.254

4.  Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study.

Authors:  Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Andrew C Leon; David A Solomon; William Coryell; Jack D Maser; Martin B Keller
Journal:  Arch Gen Psychiatry       Date:  2005-12

5.  A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.

Authors:  Katharine A Phillips; Ralph S Albertini; Steven A Rasmussen
Journal:  Arch Gen Psychiatry       Date:  2002-04

6.  Psychosocial disability during the long-term course of unipolar major depressive disorder.

Authors:  L L Judd; H S Akiskal; P J Zeller; M Paulus; A C Leon; J D Maser; J Endicott; W Coryell; J L Kunovac; T I Mueller; J P Rice; M B Keller
Journal:  Arch Gen Psychiatry       Date:  2000-04

7.  Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study.

Authors:  Katharine A Phillips; Steven A Rasmussen
Journal:  Psychosomatics       Date:  2004 Sep-Oct       Impact factor: 2.386

8.  The prevalence of body dysmorphic disorder: a population-based survey.

Authors:  Winfried Rief; Ulrike Buhlmann; Sabine Wilhelm; Ada Borkenhagen; Elmar Brähler
Journal:  Psychol Med       Date:  2006-03-06       Impact factor: 7.723

9.  An open-label study of citalopram in body dysmorphic disorder.

Authors:  Katharine A Phillips; Fedra Najjar
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

10.  The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

Authors:  M B Keller; P W Lavori; B Friedman; E Nielsen; J Endicott; P McDonald-Scott; N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1987-06
View more
  10 in total

Review 1.  Body dysmorphic disorder: some key issues for DSM-V.

Authors:  Katharine A Phillips; Sabine Wilhelm; Lorrin M Koran; Elizabeth R Didie; Brian A Fallon; Jamie Feusner; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

2.  Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.

Authors:  Katharine A Phillips; Aparna Keshaviah; Darin D Dougherty; Robert L Stout; William Menard; Sabine Wilhelm
Journal:  Am J Psychiatry       Date:  2016-04-08       Impact factor: 18.112

3.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

4.  Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.

Authors:  K A Phillips; S L McElroy; M M Dwight; J L Eisen; S A Rasmussen
Journal:  J Clin Psychiatry       Date:  2001-02       Impact factor: 4.384

5.  Personal and appearance-based rejection sensitivity in body dysmorphic disorder.

Authors:  Megan M Kelly; Elizabeth R Didie; Katharine A Phillips
Journal:  Body Image       Date:  2014-04-13

6.  Predictors of Response to Cognitive-Behavioral Therapy for Body Dysmorphic Disorder.

Authors:  Jennifer L Greenberg; Katharine A Phillips; Gail Steketee; Susanne S Hoeppner; Sabine Wilhelm
Journal:  Behav Ther       Date:  2019-01-10

7.  Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder: A Randomized Clinical Trial.

Authors:  Sabine Wilhelm; Katharine A Phillips; Jennifer L Greenberg; Sheila M O'Keefe; Susanne S Hoeppner; Aparna Keshaviah; Suraj Sarvode-Mothi; David A Schoenfeld
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 21.596

8.  Body Dysmorphic Disorder: Clinical Overview and Relationship to Obsessive-Compulsive Disorder.

Authors:  Katharine A Phillips; Megan M Kelly
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-11-05

9.  Shame and Defectiveness Beliefs in Treatment Seeking Patients With Body Dysmorphic Disorder.

Authors:  Hilary Weingarden; Ashley M Shaw; Katharine A Phillips; Sabine Wilhelm
Journal:  J Nerv Ment Dis       Date:  2018-06       Impact factor: 2.254

Review 10.  Body dysmorphic disorder.

Authors:  Andri S Bjornsson; Elizabeth R Didie; Katharine A Phillips
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.